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Abstract
Germ cell development and primordial follicle formation during fetal life is critical in estab-
lishing the pool of oocytes that subsequently determines the reproductive lifespan of
women. Fragile X-associated primary ovarian insufficiency (FXPOI) is caused by inheri-
tance of the FMR1 premutation allele and approximately 20% of women with the premuta-
tion allele develop ovarian dysfunction and premature ovarian insufficiency. However, the
underlying disease mechanism remains obscure, and a potential role of FMRP in human
ovarian development has not been explored. We have characterised the expression of
FMR1 and FMRP in the human fetal ovary at the time of germ cell entry into meiosis
through to primordial follicle formation. FMRP expression is exclusively in germ cells in the
human fetal ovary. Increased FMRP expression in germ cells coincides with the loss of
pluripotency-associated protein expression, and entry into meiosis is associated with
FMRP granulation. In addition, we have uncovered FMRP association with components of
P-bodies and stress granules, suggesting it may have a role in mRNA metabolism at the
time of onset of meiosis. Therefore, this data support the hypothesis that FMRP plays a
role regulating mRNAs during pivotal maturational processes in fetal germ cells, and ovar-
ian dysfunction resulting from FMR1 premutation may have its origins during these stages
of oocyte development.
Introduction
Female reproductive senescence largely results from the depletion of a finite ovarian follicle
pool that is established during fetal life. In humans, these follicles are produced from primor-
dial germ cells, which migrate to the gonadal ridge by the 5th week of gestation, proliferate and
develop into oocytes [1]. The transition from primordial germ cells to oocytes occurs from the
11th week of gestation and is marked by a loss of pluripotencymarkers including OCT4 and
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LIN28 [2], incomplete cytokinesis with formation of germ cell nests and entry into meiosis [3,
4]. Oocytes progress through the first few stages of meiotic prophase I before arresting at diplo-
tene, and following germ cell nest breakdown, are subsequently enclosed by a layer of pregra-
nulosa cells, thus forming primordial follicles, from around 17 weeks gestation onwards [5].
Oocyte development in the human fetal ovary is relatively asynchronous, with a developmental
gradient forming: pre-meiotic oogoniamainly reside in the more superficial ovarian cortex
while differentiated oocytes and newly formed primordial follicles are located towards the
ovarian medulla [6]. These follicles are then activated into the growth phase over the reproduc-
tive lifespan, culminating in their depletion which signals the menopause.
Premature (also termed primary) ovarian insufficiency (POI) is defined as the cessation of
menses with evidence of follicle depletion before the age of 40, and has both environmental
and genetic causes (reviewed in [7]). One such genetic cause is the expansion of a CGG trinu-
cleotide repeat in the 5’ untranslated region (UTR) of the FMR1 gene, resulting in the disorder
known as fragile X-associated primary ovarian insufficiency (FXPOI) [8]. The FMR1 allele is
susceptible to expansion during germline transmission [9]; a full mutation (defined as>200
CGG repeats) of FMR1 leads to an absence or deficiency of the FMR1 protein (FMRP) through
epigenetic silencing of the gene, and is the prime cause of fragile X syndrome, while a premuta-
tion (55–200 CGG repeats) is characterised by elevated FMR1 transcript expression [10].
Approximately 20% of women who carry the premutation allele have FXPOI [11, 12]. Prior to
the onset of POI, premutation carriers have abnormal ovarian reserve biomarkers and a
reduced response to controlled ovarian stimulation [13], indicating a depleted follicle pool.
The origins and onset of ovarian dysfunction in women with FXPOI are unknown, and no
extended expression analysis of FMRP has been performed in the human fetal ovary. However,
FMRP expression has been reported in ovarian germ cells of a 19 week old fetus carrying the
full mutation and a miscarried 24 week old human fetus without fragile X syndrome; from neo-
natal to adult the protein has only been observed in granulosa cells [14, 15]. In mice, FMRP is
present in both oocytes and granulosa cells of adult ovaries [16–18]. Two knock-inmouse
models for the FMR1 premutation have demonstrated that an intermediate length of CGG
repeats is sufficient to impair female fertility [16, 19]. These mice showed an increased rate of
follicular atresia indicating increased follicle activation and loss, and exhibit increased and
decreased serum concentrations of FSH and 17β-estradiol respectively, which reflect the hor-
monal changes seen in human POI patients. Fmr1 null mice have enlarged ovaries and exhibit
precocious follicular activation [20]. Although Fmr1mRNA is expressed in the fetal ovary,
mice with the premutation are reported to have a normal primordial follicle pool, though this
is depletedmore quickly than in wildtypemice, leading to ovarian insufficiency.Whether this
is due to an intrinsic abnormality within the oocytes or pre-granulosa cells of primordial folli-
cles, or in the pathways that control follicle activation is unclear, as is its possible relevance to
human primordial follicle formation and oocyte development [21].
FMRP is an RNA binding protein that regulates mRNA translation as well as the transport
and stability of its mRNA targets in neurons [17, 22]. In these cells, FMRP is a component of
several different mRNA ribonucleotide particles (mRNP) containing granules: namely, stress
granules [23], processing bodies (P-bodies) [24] and neuronal granules [25]. These granules
are thought to play key roles in mRNA storage, turnover and localisation. A fourth type of
RNA granule, the germ cell granule, is an evolutionary conserved feature of germ cell cyto-
plasm and critical for gametogenesis [26]. Within these granules, target mRNAs are associated
with RNA binding proteins that control whethermRNAs are stored, translated and/or
degraded [27]. This is particularly important for growing oocytes in mammals, as de novo syn-
thesis of transcripts ceases as they enter meiosis, and subsequent changes in protein production
is highly dependent on regulated translation of stored mRNAs [28–30].
FMRP in the Human Oocyte
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As germ cell development and primordial follicle formation are critical in establishing life-
long reproductive potential, and the potential importance of FMRP in this process, we have
explored the expression of FMR1mRNA and of its two paralogues FXR1 and FXR2, and FMRP
in the human fetal ovary at these developmental stages. By characterising the expression and
localisation of FMRP in developing germ cells, and its relationship to markers of these various
granule types, we hoped to gain insight into how the FMR1 premutation may affect human
oocyte development and/or folliculogenesis.
Results
Expression of FMR1 and FMRP increases during human fetal ovarian
development
Expression of FMR1 and its two paralogues FXR1 and FXR2was assessed in 8–11 weeks gesta-
tional age (wga), 14-16wga and 18-20wga human fetal ovaries using RT-qPCR, as these stages
encompass key stages of germ cell development, specifically primordial germ cell proliferation,
entry into meiosis and initiation of primordial follicle formation, respectively. FMR1 transcript
levels increased between 8-11wga and 14-16wga (p<0.05) and this expression continued to
increase at 18-20wga (p<0.0001; Fig 1A). This change in expression across gestation was also
shown for FXR2, however transcript levels were only significantly different between 8-11wga
and 18-20wga (p<0.05). No changes were seen in the expression of FXR1 across development.
Examination of FMRP expression using immunohistochemistry revealed abundant staining in
14wga and 17wga tissue compared to 9wga tissue (Fig 1B–1D), consistent with increasing
FMR1 transcript levels during this period. FMRP expression was observed exclusively in the
germ cell cytoplasm across the range of gestations examined and was maintained after germ
cell nest breakdown and follicle formation (Fig 1D insert). No FMRP expression was observed
in granulosa or other ovarian somatic cells, or the negative control (data not shown).
Changes in FMRP expression and distribution coincides with the
developmental progression of primordial germ cells
Double immunofluorescencewas used to further characterise FMRP expression in relation to
germ cell development frommitotic proliferation through to entry into meiosis. There was lim-
ited overlap between the expression of primordial germ cell/pluripotency-associatedmarkers
OCT4 or LIN28 with FMRP (Fig 2A and 2B), indicating little FMRP expression in premeiotic
germ cells. At 14–16 wga, approximately 17% of OCT4 positive cells and 9% of LIN28 cells also
expressed FMRP, and in these instances FMRP staining was weak and diffuse. Consistent with
increased expression in more mature germ cells, FMRP-expressing germ cells were predomi-
nantly located towards the medulla of the fetal ovary. This was confirmed by co-expression of
FMRP with the meiotic marker SYCP3 (Fig 2C). Strikingly, the cytoplasmic distribution of
FMRP changed from diffuse to granular in SYCP3 positive germ cells. Less than 0.1% of
SYCP3 positive cells had diffuse FMRP staining. Therefore, the developmental transition from
primordial germ cells expressing OCT4 and/or LIN28 to meiotic germ cells coincidedwith
increased expression of FMRP and formation of FMRP-rich foci (Fig 2D).
FMRP granules in fetal ovary show variable degrees of co-localisation
with stress granule and P-body markers
Given that FMRP could be localised to a range of mRNP granules in somatic cells, we
attempted to directly visualise RNA granules by in situ hybridisation, but this did not provide
the necessary resolution (data not shown). Therefore, the FMRP-rich foci observed in human
FMRP in the Human Oocyte
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fetal germ cells were further characterisedwith double immunofluorescenceusing an array of
known stress granule or P-body protein components. Although these granules are distinct and
can be identified by specificmarkers, they are also dynamic and share somemRNA and protein
components [31]. The P-body marker DCP1awas diffuse in the cytoplasm of both germ and
somatic cells and its distribution did not overlap with FMRP (Fig 3A). DDX6, another P-body
marker, was only found in germs cells. There was limited overlap betweenFMRP granules and
DDX6, whichmay reflect the diffusenature of the DDX6 staining (Fig 3B). Similarly, partial over-
lap in expression with FMRP granules was observedwith the stress granulemarker PABP1, as its
expression was detected in the germ cell cytoplasmwhere its staining too was diffuse (Fig 3D). In
contrast, the P-body marker GW182 was distinctly granular in the majority of germ cells and co-
localisedwith a small proportion of FMRP granules (Fig 3C), as did that of G3BP, another stress
granulemarker, which also demonstrated granular expression in the germ cell cytoplasm (Fig 3E).
Triple immunofluorescence against FMRP, GW182 and G3BP was therefore performed to
investigate further the distribution of FMRP in foci containing P-body and stress granules
Fig 1. Expression of FMR1, FXR1, FXR2 and FMRP in human fetal ovaries. A. mean ovarian mRNA levels of FMR1 and its paralogues
FXR1 and FXR2 among 8–10 (n = 5), 14–16 (n = 5) and 17–20 (n = 5) weeks of gestation. Error bars in histograms represent ±SEM. B-D.
Immunohistochemical localisation of FMRP in human fetal ovaries at 9, 14 and 17 wga. FMRP is expressed in the cytoplasm of germ cells at all
gestations examined, with its expression maintained in newly formed primordial follicles (D, insert). Black arrowheads indicate germ cell nests.
Black arrow indicates primordial follicle. Scale bars: 50μm
doi:10.1371/journal.pone.0163987.g001
FMRP in the Human Oocyte
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markers (Fig 4A). The relationship between granule components is depicted in Fig 4B. 16.6%
and 15.5% of FMRP foci co-expressed either G3BP or GW182, respectively, while 9.4% of
Fig 2. Immunohistochemical co-localisation of FMRP and primordial germ cell or meiosis markers in fetal ovaries at 14-16wga. A. FMRP
and the pluripotency marker OCT4 are expressed in distinct germ cell subpopulations with only few germ cells co-expressing OCT4 and FMRP.
OCT4-positive cells are located closer to the cortex and FMRP-positive cells are closer to the medulla. Note the granular distribution of FMRP (white
arrowheads). B. As with OCT4, there is limited overlap between FMRP and the primordial germ cell-specific marker LIN28. Note that in germ cells co-
expressing FMRP and LIN28, FMRP distribution is not granular (white arrow). C. Expression of the meiosis marker SYCP3 correlates with FMRP
granulation (white arrowheads) in most but all of germ cells, suggesting that FMRP granulation precedes SYCP3 expression. D. Diagram outlining
FMRP expression and granulation in germ cell development from primordial germ cells (PGCs) to meiotic oocytes. Abbreviations: ct, cortex; md,
medulla. Scale bars: 50μm. Pictures are representatives from at least five different ovaries.
doi:10.1371/journal.pone.0163987.g002
FMRP in the Human Oocyte
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Fig 3. Immunohistochemical co-localisation of FMRP and P-body or stress granule markers in 2nd trimester human fetal ovaries. Yellow
signal indicates co-localisation. A. FMRP and the P-body marker DCP1a are expressed in distinct compartments within germ cells and no expression
overlap is evident. B. The distribution of the P-body marker DDX6 is generally diffuse; some degree of co-localisation between FMRP granules and
DDX6 is evident, possibly the result of random association of DDX6 with FMRP. C. The distribution of the P-body marker GW182 is distinctly granular
in the human fetal ovary and there is a degree of association of GW182 and FMRP granules (white arrowheads). D. The distribution of the stress
granule marker PABP1 is more diffuse towards the cortex and more granular towards the medulla; as with GW182, some PABP1 granules co-
localise with FMRP granules. E. The distribution of the stress granule marker G3BP is distinctly granular. A portion of FMRP granules co-localise with
G3BP Abbreviations: ct, cortex; md, medulla. Scale bars: 50μm. Pictures are representatives from at least five different ovaries.
doi:10.1371/journal.pone.0163987.g003
FMRP in the Human Oocyte
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FMRP granules co-localisedwith both granule components. GW182 granules showed a limited
degree of co-localisationwith G3BP granules (Fig 4B) and in those instances, FMRP was also
present in a majority (75.5%), suggesting that FMRPmay not only be a dynamic component of
a subset of P-body and S-granules but may also be exchanged between them or play a role in
promoting their fusion.
Discussion
Establishment of the primordial follicle pool during fetal life is key in underpinningwomen’s
reproductive potential. Factors affecting both the quality and quantity of the ovarian reserve
may significantly impact a woman’s fertility and her ability to conceive. Premutation of FMR1
is implicated in human FXPOI, and female transgenic mice harbouring the premutation allele
have impaired fertility [16, 19]. However, the timing of onset of ovarian dysfunction in FXPOI,
and the stage(s) of follicle development it perturbs are unknown.We therefore sought to
extend the present knowledge of FMRP expression to an earlier stage of ovarian development,
thus providing insight into how disruption of FMRP expression prior to, or during the estab-
lishment of the ovarian reservemay contribute to FXPOI.
We studied the expression of FMR1, and its protein product FMRP, in the ovaries of human
fetuses, from primordial germ cell proliferation through onset of meiosis to primordial follicle
formation. FMRP expression was widespread in oocytes in ovaries at 14–17 weeks gestation,
including in those within newly formed primordial follicles at the latest gestations examined.
The increase in both FMR1mRNA and FMRP across gestation, the specific expression of
FMRP in germ cells, and the marked change in expression within germ cells at the onset of
meiosis suggest that FMRP is associated with processes relating to germ cell differentiation at
this critical stage of human ovarian development. Furthermore, the specific localisation of
FMRP to the germ cell cytoplasm is consistent with roles in mRNA translation/stability/locali-
sation. We also demonstrated expression of the FMR1 paralogues FXR1 and FXR2, the former
of which also showed increasing expression with gestation; a pattern not seen for FXR2. The
proteins expressed by FXR1 and FXR2 show variable co-localisationwith FMRP [32], and are
also thought to be involved in RNA binding and processing.
The primary function of FMRP is to repress the translation of specific RNAs. Indeed, in
neuronal tissues the majority of FMRP is found in complexes that contain stalled ribosomes in
addition to its target RNAs [33]. In support of a role for FMRP in regulating translation in the
human fetal ovary, we identified a novel, stage-specific relocalisation of FMRP to distinct cyto-
plasmic granules during germ cell differentiation.We found FMRP to be diffusely distributed
in the cytoplasm of premeiotic germ cells (identified by OCT4 and LIN28 expression), but
observed a redistribution of the protein to distinct granules in meiotic germ cells (indicated by
SYCP3 expression). As no SYCP3-positive germ cells with diffuse FMRP were observed, but
SYCP3-negative germ cells with granular FMRP were evident, it seems likely that the transition
from diffuse to granular FMRP occurs before or during the initiation of meiosis.
The composition of these FMRP-containing granules was further characterised to provide
initial insight into the biological pathways they might participate in during germ cell matura-
tion. Of the markers employed, G3BP and GW182 were the most informative and showed var-
ied degrees of co-localisationwith FMRP granules. G3BP is typically found in stress granules,
which are thought to act as repositories for mRNA storage [34]. GW182 is observed in P-bod-
ies, which are associated with miRNA-mediated gene silencing pathways that culminate in
both translational repression and mRNA degradation [35, 36]. Given that GW182-mediated
mRNA decay requires DCP1 [37], whose expression we found did not overlap with FMRP (Fig
3A), it seems likely that GW182-containing FMRP granules are not sites of miRNA-mediated
FMRP in the Human Oocyte
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Fig 4. Immunohistochemical co-localisation of FMRP, GW182 and G3BP in human fetal ovaries at 15 wga. A. Yellow signal indicates co-
expression of G3BP and GW182. Cyan signal indicates co-expression of GW182 and FMRP. Magenta signal indicates co-expression of G3BP and
FMRP. White signal indicates co-expression of G3BP, GW182 and FMRP. B. Venn diagram depicting the relationship between granule
components. The majority of granules positive for both G3BP and GW182 contained FMRP (75.5%).
doi:10.1371/journal.pone.0163987.g004
FMRP in the Human Oocyte
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degradation but rather foci of miRNA-mediated translational repression. The appearance of
these granules at the onset of meiosis raises the possibility that FMRP is repressing mRNAs
whose translation must be silenced to allow the mitosis-meiosis transition. Moreover, the
observation of granules that contained both G3BP and GW182 may reflect the dynamic nature
of stress granules and P-bodies, which can physically interact with each other, leading to the
speculation that repressed FMRP-bound mRNAs can be transferred from stress granules to P-
bodies for storage or degradation [31, 38]. As FMRP was found in the majority of granules con-
taining both G3BP and GW182, it may have a role in the association of stress granules and P-
bodies in human ovarian germ cells or even the co-ordination of the movement of some of its
target mRNAs between these granules, as it does in hippocampal neurons [39]. Determining
the functional significance of these granules in meiosis will require the identification of relevant
target mRNAs, as no RNA targets of FMRP in the fetal ovary have been described.
The localisation of FMRP granules to germ cell cytoplasm leads to the hypothesis that these
structures are in fact, a class of germ cell granule, as these share many components with stress
granules and P-bodies, including GW182 [40]. Loss of RNAs found in these granules causes
failure of primordial germ cell migration, reduced germ cell proliferation, pre-meiotic germ
cell death, and meiotic defects [41–46]. However the molecularmechanisms that underlie
germ cell granule involvement in these phenotypes is unclear and mammalian germ cell gran-
ules remain poorly understood.
Translational control of mRNA plays a central role in regulating gene expression during
oogenesis: during their growth phase, mammalian oocytes are transcriptionally active but
mRNA synthesis drops to very low or undetectable levels at the onset of meiosis [47]. Loss of
this translational control, which may occur in FXPOI patients, may have more global effects
and secondary consequences through the dysregulation of primarymRNA targets of FMRP.
These results provide a basis for this occuring during fetal life, with consequences for the qual-
ity and quantity of the follicular reserve.
In conclusion, the changes in FMR1mRNA expression and FMRP localisation at the time
of transition frommitosis to meiosis in the human fetal ovary, suggests that FMRP is associated
with important maturational processes in germ cells, and dysfunction resulting from FMR1
premutation may have its origins at this stage of oocyte development. The biological function
of FMRP granules in human fetal oocytes is unclear, yet since they associate with components
of P-bodies and stress granules it is likely that they are involved in mRNA metabolism at the
time of onset of meiosis, such as the repression and/or destruction of mRNAs required for the
mitosis-meiosis transition.
Materials and Methods
Ethics statement
Ethical approval for this study was obtained from Lothian Research Ethics Committee (study
code LREC 08/S1101/1) which oversees research in Edinburgh, and women gave informed
written consent.
Collection of human fetal ovaries
Human fetuses (8–20 weeks gestational age (wga)) were obtained directly from patients at local
hospitals after elective termination of pregnancy, and all fetuses used in this study were mor-
phologically normal. Gestational age was determined by ultrasound scan, and confirmed (for
second trimester fetuses) by direct measurement of foot length. The sex of first trimester fetal
gonads was determined by PCR for the SRY gene [48]. Extra-ovarian tissue was removed from
dissected ovaries, which were then either snap frozen on dry ice and stored at -80°C for
FMRP in the Human Oocyte
PLOS ONE | DOI:10.1371/journal.pone.0163987 October 3, 2016 9 / 14
subsequent RNA extraction, or fixed in Bouins or 4% neutral buffered formalin (NBF) for 2–3
hours before processing into paraffin blocks for immunohistochemical analysis.
RNA extraction, cDNA synthesis and RT-qPCR
RNA was extracted with the RNeasy Micro Kit (Qiagen, Crawley, UK; Cat #74004). cDNA was
prepared using the Maxima1 First Strand cDNA Synthesis Kit (Fermentas, Loughborough,
UK; #K1642) according to the manufacturer’s specifications. RT-qPCRs were performed using
the Brilliant III Ultra-Fast QRT-PCR (Agilent Technologies, Stockport, UK; #600880) in 10μl
volumes according to the manufacturer’s instructions. Primers are outlined in Table 1. Primer
pair efficiencieswere calculatedwith the LinReg PCR applet [49]. Each reaction was performed
in a final volume of 10 μL, with 1x Brilliant III SYBR Green qPCRMaster Mix (Agilent Tech-
nologies, Santa Clara, CA, USA), 20pmol of each primer and 2 μL of diluted cDNA. Each
cDNA sample was analysed in triplicate. Target genes were normalised to the expression of
RPL32. Data analysis for relative quantification of gene expression and calculation of standard
deviations was performed as outlined by [50].
Immunohistochemistry
All antibodies, visualisation dyes, their dilutions and source information are given in Table 2.
5 μm thick fetal ovary tissue sections were de-waxed and antigen retrieval was performed in
10mM sodium citrate buffer using pressure cooker (125°C for 30s, then 90°C for 10s). In each
case, peroxidase block was performed using DAKO REAL Peroxidase block (DAKO, Cam-
bridge, UK; #5203) for 10min, followed by a biotin/streptavidin block (Vector Laboratories,
Peterborough, UK; #SP2002) according to the manufacturer’s guidelines.
For 3,3'-Diaminobenzidine tetrahydrochloride (DAB) detection, sections were rinsed in
Tris-buffered saline (TBS), blocked in 20% normal goat serum+ 5% bovine serum albumin
(BSA) (Sigma-Aldrich, Poole, UK) in TBS (NGS/BSA/TBS) for 30min, and incubated with
anti-FMRP antibody diluted in NGS/BSA/TBS overnight. The following day sections were
washed 1 x 5min in TBS + 0.05% Triton X-100 (Sigma-Aldrich), followed by 1 x 5min in TBS.
The appropriate biotin-conjugated secondary antibody was diluted in NGS/BSA/TBS, applied
to the section for 30min and washed as above. Streptavidin-conjugate horseradish peroxidase
(HRP) was diluted in TBS and applied on the sections for 30min and again washed as above.
DAB detectionwas then carried using the Liquid DAB + Substrate Chromogen System accord-
ing to the manufacturer’s instructions. Staining was examined under a microscope and the
reaction stopped by transferring to TBS when staining reached desired intensity. Sections were
counterstained with haematoxylin, dehydrated and mounted using Pertex (CellPath Ltd, New-
town Powys, UK).
For double immunofluorescence, the first primary antibody used was either anti-OCT4,
anti-LIN28, anti-SYCP3, anti-DCP1a, anti-DDX6, anti-GW182 or anti-PABP1, and the second
primary applied was anti-FMRP. Sectionswere rinsed in phosphate-buffered saline (PBS),
blocked in 20% goat serum+ 5% BSA in PBS (NGS/BSA/PBS) for 30min and incubated with
Table 1. Sequences of forward and reverse primers for real time PCR.
Gene Forward Reverse
FMR1 CAGGGCTGAAGAGAAGATGG ACAGGAGGTGGGAATCTGA
FXR1 GGTTGGCTAAAGTTCGGATG TAGCACACGCCTCTCTCAAA
FXR2 AGGGGATGAAGTGGAGGTTT GAAGAAGCTGCCTTTGGTTG
RPL32 CATCTCCTTCTCGGCATCA AACCCTGTTGTCAATGCCTC
doi:10.1371/journal.pone.0163987.t001
FMRP in the Human Oocyte
PLOS ONE | DOI:10.1371/journal.pone.0163987 October 3, 2016 10 / 14
the first primary antibody diluted as indicated in Table 2 in NGS/BSA/PBS overnight. The fol-
lowing day sectionswere washed 1 x 5min in PBS + 0.05% Triton X-100, followed by 1 x 5min in
PBS. The appropriate peroxidase-conjugated secondary antibody was diluted in NGS/BSA/PBS,
applied to the section for 30min and washed as above. Cy3-conjugated tyramide was applied on
the sections according to the manufacturer’s specifications for 10min, after which time sections
were washed as above. Tissue-bound antibodies were denatured by microwaving sections in
10mM sodium citrate buffer for 4min at high-power, followed by 4min at medium power and
left to cool for 20-30min. Sectionswere blocked, incubated overnight with the second primary
(anti-FMRP) diluted in NGS/BSA/PBS and washed in the samemanner as the first primary. Bio-
tinylated Goat anti-rabbit was diluted in NGS/BSA/PBS and applied to the sections for 30min,
followed by washes as above. Alexa Fluor488-streptavidin conjugate was diluted in NGS/BSA/
PBS, applied to the sections for 60min and rinsed as above. Nuclei were counter stained with
DAPI (diluted in PBS) for 10-20min, and sectionswere washed as above and mounted in Perma-
fluor (Thermo Scientific,Asheville, North Carolina, USA). Triple immunofluorescencewas con-
ducted as above probing sections sequentially with anti-GW182, anti-G3BP and anti-FMRP
primaries. Each primarywas detected using Cy3-conjugated tyramide, Cy5-conjugated tyramide
and Alexa Fluor488-conjugated streptavidin respectively. FMRP, G3BP and GW182 granules
and their double and triple combinations were counted in a field of view of 0.05mm2 from three
stained ovarian sections spanning 14–16 wga using ImageJ.
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Table 2. Primary antibodies, secondary antibodies and fluorescent dyes used.
Primary Antibodies Dilutions Catalogue # Company
DAB fluorescence
rabbit anti-FMRP 1 in 2000 1 in 250 ab17722 Abcam, Cambridge, UK
mouse anti-OCT4 1 in 700 sc-5279 Santa Cruz Biotechnology, SantaCruz, USA
rabbit anti-LIN28 1 in 10,000 ab46020 Abcam Cambridge, UK
rabbit anti-SYCP3 1 in 50,000 ab150292 Abcam Cambridge, UK
rabbit anti-DCP1a 1 in 6,000 ab47811 Abcam Cambridge, UK
rabbit anti-DDX6 1 in 8,000 A300-461A Cambridge Bioscience, Cambridge, UK
mouse anti-G3BP 1 in 16,000 611126 BD Biosciences, Erembodegem, Belgium
mouse anti-GW182 1 in 500 sc-56314 Santa Cruz Biotechnology, Santa Cruz, USA
rabbit anti-PABP1 1 in 6,000 N/A from Prof. Nicola Gray
Secondary Antibodies
biotinylated goat anti-rabbit 1 in 500 1 in 500 E0432 Dako, Cambridge, UK
biotinylated goat anti-mouse 1 in 500 BA-9200 Vector, Peterborough, UK
Peroxidase-conjugated goat anti rabbit 1 in 500 P0448 Dako, Cambridge, UK
Peroxidase-conjugated goat anti-mouse 1 in 500 P0447 Dako, Cambridge, UK
Streptavidin-conjugated HRP 1 in 1000 SA-5004 Vector, Peterborough, UK
Visualisation Dyes
streptavidin-conjugated Alexa Fluor 488 1 in 500 S-11223 Life Technologies Ltd, Paisley, UK
Cy3-conjugated Tyramide 1 in 50 NEL744B001KT Perkin Elmer, Cambridge, UK
Cy5-conjugated Tyramide 1 in 50 NEL745B001KT Perkin Elmer, Cambridge, UK
Liquid DAB + Substrate Chromogen System N/A K3468 Dako, Cambridge, UK
DAPI 1 in 1000 D9542 Sigma-Aldrich, Dorset, UK
doi:10.1371/journal.pone.0163987.t002
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